Ⓐ
PeptiBrief
Randomized controlled trial· 2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al.

New England Journal of Medicine

DOI
10.1056/nejmoa2032183
PubMed
33567185
Evidence level
high
Verification
verified

Summary

Double-blind randomized trial comparing once-weekly semaglutide 2.4 mg with placebo plus lifestyle intervention for 68 weeks in adults with overweight or obesity without diabetes.

Limitations

The trial excluded diabetes, lasted 68 weeks and was conducted with structured lifestyle support. Results do not establish outcomes after indefinite treatment or after withdrawal.

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.